Company intelligence / Profile preview

NeuroMane

Ownership: Private
Development stage: Commercial

Overview

NeuroMane offers nano-formulated Lion’s Mane mushroom and Kava extracts as dietary supplements. The company claims enhanced bioavailability and potential benefits for memory, focus, cognitive function, immune response, inflammation reduction, nerve cell repair, energy/stamina boost, blood sugar management, fatigue reduction and anxiety relief. No clinical trial data or regulatory approvals were identified.

Therapeutic areas: PsychiatryImmunologyNeurology
Modalities: Natural extractNano-formulated supplementMushroom-derived productPlant extract supplement
Industry: Food & Nutrition

Drug pipeline

2 assets

NeuroMane

Commercial

Indications: Cognitive decline, Memory loss, Anxiety

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on NeuroMane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroMane.

Explore the full profile